About this trial
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
Eligibility criteria
Qualifiers
Age 18 years or older
Treating physician has decided to start continuous infusion of cloxacillin
Disqualifiers
Unwilling or unable to provide written informed consent
Trial design
Treatments tested in this trial
- Unbound cloxacillin concentration
Treatment groups
Locations
1Sponsors and collaborators
Emeli Månsson
Lead sponsor
Region Västmanland
Sponsor institution
Region Västmanland
Collaborator